News | November 09, 2023
Bayer posts Q3 2023 Group sales Euro 10.34 billion
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
The European Commission approved the use of Carbopol as an additive for liquid and solid food supplements in the EU
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Subscribe To Our Newsletter & Stay Updated
